ICCCImmuCell Corporation

$60M

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+53.1% YoY

Gross Profit

$2M49.9% margin

Operating Income

$265,3046.0% margin

Net Income

$144,5553.3% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+50.2%

Cash Flow

Operating Cash Flow

$677,197

Free Cash Flow

$482,794

Stock-Based Comp.

$82,835

Balance Sheet

Total Assets

$40M

Total Liabilities

$10M

Stockholders' Equity

$30M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$3M	+53.1%
Gross Profit	$2M	$1M	+61.9%
Operating Income	$265,304	-$178,155	+248.9%
Net Income	$144,555	-$221,123	+165.4%

ICCC Q1 2019 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena